Eli Lilly & Co. (LLY)
Eli Lilly & Co. is a global pharmaceutical company founded in 1876, focused on developing innovative medicines in areas such as oncology, neuroscience, diabetes, and immunology. The company is known for its research-driven approach and has a strong portfolio of prescription drugs and biologics aimed at improving patient health worldwide.
Dividend History
Investors can expect a dividend payout of $1.50 per share, scheduled to be distributed in 19 days on December 10, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 10, 2025 | $1.50 | 2025-11-14 | 2025-11-14 |
| September 10, 2025 | $1.50 | 2025-08-15 | 2025-08-15 |
| June 10, 2025 | $1.50 | 2025-05-16 | 2025-05-16 |
| March 10, 2025 | $1.50 | 2025-02-14 | 2025-02-14 |
| December 10, 2024 | $1.30 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- Eli Lilly & Co. has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 72 days ago, on September 10, 2025
- The highest dividend payed out to investors during this period was $1.50 per share
- The average dividend paid during this period was $0.65 per share.
Company News
Pfizer's high dividend yield of 6.9% remains safe for now, but investors are cautious about the company's future growth prospects following reduced COVID-19 product sales and potential upcoming patent challenges.
Healthcare stocks are experiencing a sector rotation as investors move away from tech, with three large-cap pharmaceutical companies showing strong potential due to attractive valuations, breakthrough drugs, and promising earnings.
Tech stocks experienced a significant downturn on Tuesday, with the Nasdaq 100 dropping over 1%, while healthcare stocks like Eli Lilly and Amgen saw gains amid market rotation and uncertainty around Fed policy and upcoming earnings.
LifeMD announced lower cash-pay pricing for Wegovy and Ozempic medications at $199 per month, supporting patients paying out of pocket through its Weight Management Program in collaboration with Novo Nordisk.
Novo Nordisk and Eli Lilly have both cut prices on their weight-loss drugs Wegovy and Zepbound, respectively, in an apparent price war to attract more customers.
